Treat Mesothelioma – The University Hospital of Lille, national expert center on pleural cancer, presented the encouraging results of a study conducted on 125 patients suffering from a primary tumor of the pleura due to asbestos.
The prognosis of pleural cancer is among the worst of all cancers, the 5-year relative survival rate of patients diagnosed between 1989 and 1997 is only 7%.
At the last ASCO board in Chicago, Professor Arnaud Scherpereel of Lille University Hospital, which is the national expert center on pleural cancer, presented two promising procedures to Treat Mesothelioma.
PUREURAL MALOTHESIS: ASBESTOS CANCER
For this study, 125 patients treated for non-operable malignant pleural mesothelioma were followed in 21 centers in France, from March to August 2016.
Malignant pleural mesothelioma is the most common primary tumors of the pleura characterized by multiplication of cancer cells in the tissue constituting the pleura (the membrane that surrounds the lungs).
More than 80% of mesothelioma cases are due to asbestos exposure that may have occurred several decades before the disease developed. In the majority of cases, the diagnosis of malignant pleural mesothelioma is made only too late, because the clinical manifestations are not very specific and occur only at an advanced stage which makes it even harder to Treat Mesothelioma.
TUMOR DECREASE AND INCREASE IN SURVIVAL
After their chemotherapy, the 125 patients received immunotherapy. Two protocols were under study to Treat Mesothelioma: nivolumab monotherapy or nivolumab in combination with ipilimumab.
- This study to Treat Mesothelioma was demonstrated a 12-week stabilization rate of 44.4% for nivolumab-treated patients and 50% for nivolumab plus ipilimumab-treated patients. The decrease in the tumor size was 18.5% for the monotherapy group and 25.9% for the other group of patients.
- The median overall survival rate was 10.4 months in the nivolumab group while the median duration was not reached in the combined treatment group (more than 50% of the patients were alive at the time of treatment).
- Survival without worsening was 4 months in the nivolumab monotherapy group and 5.6 months in the combination treatment group. Regarding the safety profile, the frequency of severe adverse events was 18% in the nivolumab plus ipilimumab combination group and 9.5% in the nivolumab group.